5-(ethylsulfonyl)-2-(quinoxalin-6-yl)benzo[d]oxazole | 1118623-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-(ethylsulfonyl)-2-(quinoxalin-6-yl)benzo[d]oxazole
• 英文别名: 5-Ethylsulfonyl-2-quinoxalin-6-yl-1,3-benzoxazole
• CAS: 1118623-71-4
• 化学式: C₁₇H₁₃N₃O₃S
• 分子量: 339.375
• InChiKey: QDJHVYCDXRCKRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  94.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-喹喔啉羧酸 、 2-氨基-4-(乙硫酰基)苯酚 在 polyphosphoric acid 作用下， 以33%的产率得到5-(ethylsulfonyl)-2-(quinoxalin-6-yl)benzo[d]oxazole
  参考文献：
  名称：

  Discovery of 2-Arylbenzoxazoles as Upregulators of Utrophin Production for the Treatment of Duchenne Muscular Dystrophy

  摘要：

  A series of novel 2-arylbenzoxazoles that upregulate the production of utrophin in murine H2K cells, as assessed using a luciferase reporter linked assay, have been identified. This compound class appears to hold considerable promise as a potential treatment for Duchenne muscular dystrophy. Following the delineation of structure-activity relationships in the series, a number of potent upregulators were identified, and preliminary ADME evaluation is described. These studies have resulted in the identification of 1, a compound that has been progressed to clinical trials.

  DOI：

  10.1021/jm200135z

文献信息

• Discovery of 2-Arylbenzoxazoles as Upregulators of Utrophin Production for the Treatment of Duchenne Muscular Dystrophy
  作者：Daniel R. Chancellor、Kay E. Davies、Olivier De Moor、Colin R. Dorgan、Peter D. Johnson、Adam G. Lambert、Daniel Lawrence、Cristina Lecci、Carole Maillol、Penny J. Middleton、Gary Nugent、Séverine D. Poignant、Allyson C. Potter、Paul D. Price、Richard J. Pye、Richard Storer、Jonathon M. Tinsley、Renate van Well、Richard Vickers、Julia Vile、Fraser J. Wilkes、Francis X. Wilson、Stephen P. Wren、Graham M. Wynne

  DOI：10.1021/jm200135z

  日期：2011.5.12

  A series of novel 2-arylbenzoxazoles that upregulate the production of utrophin in murine H2K cells, as assessed using a luciferase reporter linked assay, have been identified. This compound class appears to hold considerable promise as a potential treatment for Duchenne muscular dystrophy. Following the delineation of structure-activity relationships in the series, a number of potent upregulators were identified, and preliminary ADME evaluation is described. These studies have resulted in the identification of 1, a compound that has been progressed to clinical trials.